2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma. (6th May 2023)

• Record Type: Journal Article
• Authors: Jamet, Bastien; Bodet-Milin, Caroline; Moreau, Philippe; Kraeber-Bodéré, Françoise; Touzeau, Cyrille
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 5(2023)
• Page Start: e230
• Page End: e231
• Publication Date: 2023-05-06
• Subjects: 2-[18F]FDG PET/CT -- bispecific -- flare -- multiple myeloma -- talquetamab; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004588
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: T-cell–redirecting bispecific antibodies represent a new standard of care for the treatment of triple-class refractory myeloma patients. Here, 2-[ 18 F]FDG PET/CT imaging was performed on a 61-year-old woman with relapsed myeloma to determine metabolic response to talquetamab, a GPRC5DxCD3-bispecific antibody. At day 28, monoclonal (M) component assessment confirmed very good partial response (97% monoclonal protein reduction), whereas 2-[ 18 F]FDG PET/CT imaging revealed early bone flare-up phenomena. At day 84, bone marrow aspirate, M-component assessment, and 2-[ 18 F]FDG PET/CT demonstrated complete response, confirming the early flare-up hypothesis.